PT217

CD47 inhibitor drugs in clinical trials aim to enhance cancer immunotherapy by targeting the CD47 surface checkpoint, which inhibits cancer proliferation. Despite no commercial approvals, several therapies are expected to enter the market soon, driven by increasing clinical trials and research, with the U.S. leading and China rapidly advancing in this field.

Phanes Therapeutics announced the first patient dosed in the PT886 clinical study, a first-in-class bispecific antibody targeting claudin 18.2 and CD47, combined with chemotherapy for pancreatic and gastric cancers. PT886 has received orphan drug and Fast Track designations from the FDA.

The FDA granted fast track designation to PT217 for treating ES-SCLC post-platinum-based chemotherapy. PT217, a bispecific antibody targeting DLL3 and CD47, is in phase 1 trials for SCLC, LC-NEC, and EP-NEC, aiming to enhance antitumor activity through immune system activation. The SKYBRIDGE trial evaluates its safety and efficacy in advanced refractory cancers.

Phanes Therapeutics' PT217, a bispecific antibody targeting DLL3 and CD47, received FDA Fast Track designation for treating extensive-stage small cell lung cancer (ES-SCLC). PT217, also granted orphan drug status in 2022, is in Phase I trials for SCLC, LCNEC, and EP-NECs, aiming to improve survival rates in these aggressive cancers.

Phanes Therapeutics' PT217, a bispecific antibody targeting DLL3 and CD47, received FDA Fast Track designation for treating extensive-stage small cell lung cancer (ES-SCLC) post-platinum chemotherapy. PT217, also granted orphan drug status in 2022, is in Phase I trials for SCLC, LCNEC, and EP-NECs, aiming to improve survival rates for these aggressive cancers.